Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
P/E ratio for Aeterna Zentaris Inc. (AEZS)
P/E ratio as of 2023: -2.14
According to Aeterna Zentaris Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.14. At the end of 2022 the company had a P/E ratio of -1.64.
P/E ratio history for Aeterna Zentaris Inc. from 1996 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.14 |
| 2022 | -1.64 |
| 2021 | -19.52 |
| 2020 | -13.66 |
| 2019 | -10.54 |
| 2018 | 46.18 |
| 2017 | -8.44 |
| 2016 | -5.97 |
| 2015 | -0.99 |
| 2014 | -8.55 |
| 2013 | 23.87 |
| 2012 | -9.22 |
| 2011 | -21.51 |
| 2010 | -22.42 |
| 2009 | -7.42 |
| 2008 | -1.74 |
| 2007 | -10.14 |
| 2006 | 25.28 |
| 2005 | 89.74 |
| 2004 | -240.03 |
| 2003 | -26.99 |
| 2002 | -35.43 |
| 2001 | -339.89 |
| 2000 | 1313.93 |
| 1999 | -279.32 |
| 1998 | -284.37 |
| 1997 | 0.00 |
| 1996 | 0.00 |